Maritech fucoidan to undergo new clinical trial to research immuno-modulating properties

Marinova (Tasmania, Australia) is conducting a new clinical trial, in collaboration with Nutrasource, to further explore the immunomodulatory properties of Maritech fucoidan, a marine polysaccharide found naturally in brown seaweed, in healthy adults. 

Previous research on Maritech fucoidan has shown that it may:

• Boost immune responses to vaccines
• Activate dendritic cells, natural killer cells and T cells
• Block the entry of coated viruses to cells
• Reduce lung damage commonly associated with viral infection
• Support mucosal immune health
• Dampen allergic responses
• Modulate stem cell 

The new study is designed to piggyback on existing evidence that suggests Maritech fucoidan acts as an immune priming agent by increasing cytotoxic T cells and natural killer cells, reducing the levels of inflammatory cytokine interleukin-6, and modulating the key market immunoglobulin.

“High-purity, certified organic fucoidan is already included in a multitude of innovative nutritional supplements targeting immune health,” said Marinova’s CEO and managing director, Paul Garrott, in a press release. “Marinova’s investment in this new clinical trial will deepen our understanding of the unique health benefits of Maritech fucoidan.”